Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Topic Systematic review of risk factors for nonadherence and nonpersistence to intravitreal anti–vascular endothelial growth factor (VEGF) injection therapy for neovascular age-related macular degeneration (nAMD). Clinical Relevance Lack of adherence (nonadherence) or undertreatment (nonpersistence) with respect to evidence from clinical trials remains a significant barrier to optimizing real-world outcomes for patients with nAMD. Contributing factors and strategies to address this are poorly understood. Methods Studies that reported factors for nonadherence and nonpersistence to anti-VEGF therapy as well as studies examining strategies to improve this were included. Trial eligibility and data extraction were conducted according to Cochrane review methods. Risk of bias was assessed using the Mixed Method Assessment Tool and certainty of evidence evaluated according to the GRADE Confidence in the Evidence from Reviews of Qualitative Research tool. Data were collated descriptively. Results Of the 1284 abstract results screened, 124 articles were assessed in full and 37 studies met the inclusion criteria. Definitions of nonadherence and nonpersistence varied or were not reported. Nonpersistence occurred early, with up to 50% of patients stopping treatment by 24 months. High rates of nonadherence were similarly reported, occurring in 32% to 95% of patients. Certainty of this finding was downgraded to a moderate level because of the heterogeneity in definitions used across studies. Multiple factors determine nonadherence and nonpersistence, including at the condition, therapy, patient, social/economic, and health systems/healthcare team levels. Moderate quality evidence points to lower baseline vision and poorer response to treatment as condition-related variables. The effects of other factors were of lower certainty, predominantly due to small numbers and potential biases in retrospective assessment. Although many factors are not modifiable (e.g., patient comorbidity), other factors are potentially correctable (e.g., lack of transport or mismatched patient expectations). Evidence on strategies to improve adherence and persistence is limited, but where available, these have proven effective. Conclusions Awareness of factors related to poor patient adherence and persistence in nAMD could help identify at-risk populations and improve real-world outcomes. Further work is required to develop uniform definitions and establish high-quality evidence on interventions that can be easily implemented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“12 The protocol for this systematic review was registered with the international PROSPERO database (ID: 172653) before data extraction.”
Adherence to Long-Term Therapies: Evidence for Action
De Geest, S., & Sabaté, E. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,272 · cited 1×
“14 Factors were analyzed qualitatively according to theme, but also quantitatively with an odds ratio or percentage, where reported.”
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers
Hong, Q. N., Fàbregues, S., Bartlett, G., Boardman, F., Cargo, M., Dagenais, P., Gagnon, M.-P., Griffiths, F., Nicolau, B., O’Cathain, A., et al. (2018) · Education for Information · doi:10.3233/efi-180221 · Cited by 4,737
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Adherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
Self-citationAge-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511 · cited 1×
“Indeed, the current novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic is a concern, because many patients are likely to have been or continue to be nonadherent during this period.”
Self-citationSeven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 1×
“8,9 Given the importance of encouraging ongoing and frequent injections, there is a relative lack of awareness among physicians and the health community of the barriers that lead to the inter-related phenomenon of nonadherence and nonpersistence of anti-VEGF treatment in nAMD in the real world.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“52,53 Within ophthalmology, strategies for adherence to glaucoma topical therapy have been extensively investigated, namely, simplifying regimens, lowering costs, educating patients, and involving the family and caretakers.”
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 615 · cited 4×
“The impact of cost or the fi nancial burden on treatment persistence was variable, accounting for as low as 2% in 1 large multi-country study 26 and as high as 30% in others.”
InfluentialAnti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 271
Long-term outcomes of treatment of neovascular age-related macular degeneration
Gillies, M. C., Campain, A., Barthelmes, D., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Essex, R. W., Morlet, N., & Hunyor, A. P. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.010 · Cited by 254 · cited 1×
“8,9 Given the importance of encouraging ongoing and frequent injections, there is a relative lack of awareness among physicians and the health community of the barriers that lead to the inter-related phenomenon of nonadherence and nonpersistence of anti-VEGF treatment in nAMD in the real world.”
Kim, L. N., Mehta, H., Barthelmes, D., Nguyen, V., & Gillies, M. C. (2016) · Retina · doi:10.1097/iae.0000000000001142 · Cited by 184
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.028 · Cited by 167
Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients
Ehlken, C., Helms, M., Böhringer, D., Agostini, H. T., & Stahl, A. (2017) · Clinical Ophthalmology · doi:10.2147/opth.s151611 · Cited by 161 · cited 4×
“25,28,29 In one study, which assessed nonadherence as no treatment or consultation at least every 6 weeks when using a PRN protocol, almost all patients (n ¼ 346, 95.6”
InfluentialBoulanger-Scemama, E., Querques, G., About, F., Puche, N., Srour, M., Mane, V., Massamba, N., Canoui-Poitrine, F., & Souied, E. H. (2015) · Journal Français d'Ophtalmologie · doi:10.1016/j.jfo.2014.11.015 · Cited by 124
The burden of neovascular age-related macular degeneration: a patient’s perspective
Spooner, K., Mhlanga, C., Hong, T., Broadhead, G., & Chang, A. (2018) · Clinical Ophthalmology · doi:10.2147/opth.s185052 · Cited by 121 · cited 2×
“46 Physicians ’ decision-making, including tolerance to fl uid on OCT imaging, may also be in fl uenced by a patient ’ s request to defer treatment or to in fl uence it.”
Boyle, J., Vukicevic, M., Koklanis, K., Itsiopoulos, C., & Rees, G. (2018) · Psychology, Health & Medicine · doi:10.1080/13548506.2016.1274040 · Cited by 119 · cited 3×
“40,42,43 Reasons were similar to those reported by those who had ceased treatment, including failure to notice any improvement in vision, 40,42,43 treatment burden on self and caretakers, and perceptions of being “ too old.”
Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life
Dröge, K., Muether, P. S., Hermann, M. M., Caramoy, A., Viebahn, U., Kirchhof, B., & Fauser, S. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2177-3 · Cited by 116 · cited 2×
“41 Of note, in Sweden, where treatment for nAMD is covered by the Swedish National Insurance, 50.6% of patients reportedly still discontinued treatment during the fi rst year of diagnosis.”
InfluentialObeid, A., Gao, X., Ali, F. S., Aderman, C. M., Shahlaee, A., Adam, M. K., Kasi, S. K., Hyman, L., Ho, A. C., & Hsu, J. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.3578 · Cited by 113 · cited 4×
“However, other factors such as bilaterality showed con fl icting results with some studies suggesting poorer adherence with unilateral eye involvement, 37 whereas others reported worse outcomes with bilaterally treated disease.”
InfluentialGuerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106 · cited 1×
“52,53 Within ophthalmology, strategies for adherence to glaucoma topical therapy have been extensively investigated, namely, simplifying regimens, lowering costs, educating patients, and involving the family and caretakers.”
Polat, O., İnan, S., Özcan, S., Doğan, M., Küsbeci, T., Yavaş, G. F., & İnan, Ü. Ü. (2017) · Türk Oftalmoloji Dergisi · doi:10.4274/tjo.28003 · Cited by 106 · cited 1×
“16,20,21 Synonyms used for nonadherence included “ noncompliance, ” 22,23 “ absenteeism, ” 24 and “ nonattendance.”
Patient-Centered Communication to Assess and Enhance Patient Adherence to Glaucoma Medication
Hahn, S. R. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.023 · Cited by 103 · cited 1×
“For example, instead of eliciting information about nonadherence to medication as for glaucoma management, 55 asking patients with nAMD about their intentions or willingness to stop treatment may help to identify at-risk patients and to trigger interventions before the event.”
Falk, M. K., Kemp, H., & Sørensen, T. L. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.06.031 · Cited by 97 · cited 2×
“” 25 Synonyms for nonpersistence included “ treatment discontinuation/cessation ” 18,26,27 and “ lost to follow-up ” Nonadherence was variably de fi ned as follows: No treatment or consultation with a measure of visual acuity and OCT at least every 6 weeks 28 Extreme violation of prescribed…”
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
Senra, H., Ali, Z. C., Balaskas, K., & Aslam, T. M. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3384-0 · Cited by 84 · cited 1×
“10,11 However, a comprehensive analysis has not been performed to date.”
Varano, M., Eter, N., Winyard, S., Wittrup-Jensen, K., Navarro, R., & Heraghty, J. (2015) · Clinical ophthalmology · doi:10.2147/opth.s92548 · Cited by 77 · cited 7×
“19,25 Many patients also reported fear of injections as a major barrier to treatment (n ¼ 30, 21%), with a small number also reporting discomfort after injections as a reason for avoidance.”
InfluentialLad, E. M., Hammill, B. G., Qualls, L. G., Wang, F., Cousins, S. W., & Curtis, L. H. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.014 · Cited by 68 · cited 3×
“…12 months, 30 study period, 26,27 or permanently 31 No treatment or visit at clinic for more than 4 months, 32 6 months, 15,33,34 or 12 months 35,36 No follow-up by any ophthalmologist for 3 months 28 No follow-up within a 12-month period after receiving at least 1 anti-VEGF injection 37…”
InfluentialBoyle, J., Vukicevic, M., Koklanis, K., & Itsiopoulos, C. (2015) · Psychology, Health & Medicine · doi:10.1080/13548506.2014.936886 · Cited by 68 · cited 1×
“10,11 However, a comprehensive analysis has not been performed to date.”
Subhi, Y., & Sørensen, T. L. (2017) · Journal of Ophthalmology · doi:10.1155/2017/7194927 · Cited by 67 · cited 2×
“Finally, even in geographically smaller countries such as Sweden, where there is universal free transport to hospitals, some patients still struggle to engage with their treatment, 20 which highlights the multifactorial nature of this problem.”
Ramakrishnan, M. S., Yu, Y., & VanderBeek, B. L. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.4577 · Cited by 67 · cited 1×
“38 However, when the longest interval between 2 visits was calculated, 83.3% of patients still had at least 1 visit interval that was not on time.”
InfluentialAngermann, R., Rauchegger, T., Nowosielski, Y., Casazza, M., Bilgeri, A., Ulmer, H., & Zehetner, C. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04414-y · Cited by 66 · cited 1×
“…before 12 months, 30 study period, 26,27 or permanently 31 No treatment or visit at clinic for more than 4 months, 32 6 months, 15,33,34 or 12 months 35,36 No follow-up by any ophthalmologist for 3 months 28 No follow-up within a 12-month period after receiving at least 1 anti-VEGF…”
Curtis, L. H., Hammill, B. G., Qualls, L. G., Dimartino, L. D., Wang, F., Schulman, K. A., & Cousins, S. W. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.11.032 · Cited by 64 · cited 1×
“…12 months, 30 study period, 26,27 or permanently 31 No treatment or visit at clinic for more than 4 months, 32 6 months, 15,33,34 or 12 months 35,36 No follow-up by any ophthalmologist for 3 months 28 No follow-up within a 12-month period after receiving at least 1 anti-VEGF injection 37 Loss…”
A Clinician's Guide to the Assessment and Management of Nonadherence in Glaucoma
Budenz, D. L. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.022 · Cited by 57
Vaze, A., Fraser‐Bell, S., & Gillies, M. C. (2014) · Retina · doi:10.1097/iae.0000000000000173 · Cited by 53 · cited 1×
“7 days window Nonpersistence was variably de fi ned as follows: Treatment discontinuation before 12 months, 30 study period, 26,27 or permanently 31 No treatment or visit at clinic for more than 4 months, 32 6 months, 15,33,34 or 12 months 35,36 No follow-up by any ophthalmologist for 3 months 28 No…”
Remission and Dropout Rate of Anti-VEGF Therapy for Age-Related Macular Degeneration
Oishi, A., Mandai, M., Nishida, A., Hata, M., Matsuki, T., & Kurimoto, Y. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2011.7430 · Cited by 53 · cited 1×
“17 Patient-related factors accounted for a signi fi cant cause of nonpersistence.”
Kim, J. H., Chang, Y. S., & Kim, J. W. (2017) · Retina · doi:10.1097/iae.0000000000001494 · Cited by 51 · cited 2×
“” 25 Synonyms for nonpersistence included “ treatment discontinuation/cessation ” 18,26,27 and “ lost to follow-up ” Nonadherence was variably de fi ned as follows: No treatment or consultation with a measure of visual acuity and OCT at least every 6 weeks 28 Extreme violation of prescribed…”
Best, A., Fajnkuchen, F., Nghiem‐Buffet, S., Grenet, T., Quentel, G., Delahaye-Mazza, C., Cohen, S. Y., & Giocanti‐Auregan, A. (2018) · Journal of Ophthalmology · doi:10.1155/2018/4610129 · Cited by 45
Hanemoto, T., Hikichi, Y., Kikuchi, N., & Kozawa, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189035 · Cited by 42 · cited 2×
“45,46 Overall, treatment burden, both in terms of visit frequency and travel time, was cited as the most signi fi cant barrier.”
Dröge, K., Caramoy, A., Kersten, A., Luberichs-Fauser, J., Zilkens, K., Müller, D., Kirchhof, B., & Fauser, S. (2013) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2412-6 · Cited by 33 · cited 1×
“48 However, treating ophthalmologists reported dif fi culties of some patients in understanding the proactive nature of T&E regimens.”
Heimes, B., Gunnemann, F., Ziegler, M., Gutfleisch, M., Spital, G., Pauleikhoff, D., & Lommatzsch, A. P. (2016) · Der Ophthalmologe · doi:10.1007/s00347-016-0275-z · Cited by 31 · cited 3×
“15,44 One report examined whether patients on a PRN regimen who performed their monitoring visit at a local clinic with telemedicine capabilities had better treatment adherence and increased injections compared with patients who had both monitoring and injections at the same tertiary reference…”
Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration
Westborg, I., & Rosso, A. (2017) · Ophthalmic Epidemiology · doi:10.1080/09286586.2017.1397701 · Cited by 30
Ozturk, M., Harris, M. L., Nguyen, V., Barthelmes, D., Gillies, M. C., & Mehta, H. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13085 · Cited by 29 · cited 3×
“…violation of prescribed treatment 22 Nonattendance of every clinic appointment 19 Receiving less than the recommended 8 injections over 12 months 25 Deviation from treatment recommendations (by patient or physician) with gap in treatment or consultation by more than 8 weeks 29 Visit outside of…”
InfluentialSii, S. S. Z., Aspinall, P., Borooah, S., & Dhillon, B. (2017) · Eye · doi:10.1038/eye.2017.271 · Cited by 29 · cited 1×
“40,42,43 Reasons were similar to those reported by those who had ceased treatment, including failure to notice any improvement in vision, 40,42,43 treatment burden on self and caretakers, and perceptions of being “ too old.”
Ehlken, C., Wilke, T., Bauer-Steinhusen, U., Agostini, H. T., Hasanbasic, Z., & Müller, S. (2017) · Retina · doi:10.1097/iae.0000000000001681 · Cited by 29 · cited 7×
“There was con fl icting evidence as to whether bilateral disease was a risk factor, with some studies suggesting a 3.7-fold increased risk of discontinuation if bilateral injections were required, 28,30 whereas other studies suggested that bilaterality was a protective factor.”
InfluentialLiakopoulos, S., Spital, G., Brinkmann, C. K., Schick, T., Ziemssen, F., Voegeler, J., Koch, M., Kirchhof, B., Holz, F. G., Pauleikhoff, D., et al. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315717 · Cited by 22
Gründe für Therapieverzögerung und -abbruch bei altersabhängiger Makuladegeneration
Wintergerst, M. W. M., Bouws, J., Loss, J., Heimes, B., Pauleikhoff, D., Holz, F. G., & Finger, R. P. (2017) · Der Ophthalmologe · doi:10.1007/s00347-017-0610-z · Cited by 22
Self-citationRasmussen, A., Sander, B., Larsen, M., Bloch, S. B., Fuchs, J., Hansen, L. H., & Lund‐Andersen, H. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13233 · Cited by 21 · cited 1×
“There was con fl icting evidence as to whether bilateral disease was a risk factor, with some studies suggesting a 3.7-fold increased risk of discontinuation if bilateral injections were required, 28,30 whereas other studies suggested that bilaterality was a protective factor.”
InfluentialMassamba, N., Dirani, A., Knoeri, J., Pasquier, B., Ingram, A. D., & Soubrane, G. (2015) · Eye · doi:10.1038/eye.2015.128 · Cited by 21 · cited 3×
“24 This may be due to patients weighing the bene fi ts of holidays against their eye health.”
InfluentialIida, T., & Ishii, K. (2016) · Clinical ophthalmology · doi:10.2147/opth.s120803 · Cited by 7 · cited 2×
“47 Socioeconomic factors were also prominent in these studies with caretaker productivity loss (both time and fi nancial) a signi fi cant burden.”
Krivosic, V., Philippakis, E., Couturier, A., Dupas, B., Erginay, A., Desmettre, T., Strého, M., Bonnin, S., Manne, V., Jouvaud, S., et al. (2017) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2017.03.005 · Cited by 6 · cited 2×
“15,44 One report examined whether patients on a PRN regimen who performed their monitoring visit at a local clinic with telemedicine capabilities had better treatment adherence and increased injections compared with patients who had both monitoring and injections at the same tertiary reference…”
Influential
Cited by
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785
Self-citationGene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
Self-citation
Metadata
- Authors
- Okada, M., Mitchell, P., Finger, R. P., Eldem, B., Talks, S. J., Hirst, C., Paladini, L., Barratt, J., Wong, T. Y., & Loewenstein, A.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 128
- Issue
- 2
- Pages
- 234-247
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W3047590017
- Cited by
- 214
- References
- 54
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.